Clusters of differentiation

Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts

Retrieved on: 
Thursday, May 20, 2021
Medical specialties, Toxicology, Clinical medicine, Medicine, Agenus, Hepatology, Clusters of differentiation, Occupational safety and health, Cancer immunotherapy, Toxicity, Programmed cell death protein 1, Hepatotoxicity

In this first-in-human study of AGEN2373 in patients with advanced solid tumors, no dose limiting toxicities were seen at doses up to 3 mg/kg; notably, no liver toxicity has been observed.

Key Points: 
  • In this first-in-human study of AGEN2373 in patients with advanced solid tumors, no dose limiting toxicities were seen at doses up to 3 mg/kg; notably, no liver toxicity has been observed.
  • PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.
  • Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release.
  • All forward-looking statements are expressly qualified in their entirety by this cautionary statement.\n"

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

Retrieved on: 
Wednesday, May 19, 2021
Instant messaging clients, Software, Clusters of differentiation, Immune system, CD276, Immune checkpoint, B7, Adium

B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

Key Points: 
  • B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • Under the terms of the agreement, Adium will employ its sales and marketing expertise to distribute DANYELZA and omburtamab, if approved, in the territory.
  • In addition, Adium will submit registration files on behalf of the Company in certain parts of the territory.
  • Adium distributes its products in 18 Latin American & Caribbean countries including Brazil, Mexico and Colombia.

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

Retrieved on: 
Wednesday, May 19, 2021
Clusters of differentiation, Clinical medicine, Branches of biology, Medical specialties, Immune system, Programmed cell death protein 1, PD-L1, Tumor microenvironment, Adenosine receptors, Cancer immunotherapy, Tumor-associated macrophage

"The results from this phase 1 study are very encouraging in terms of potential therapeutic role of uliledlimab to treat multiple cancers, especially in patients who do not respond to PD-1/PD-L1 therapies.

Key Points: 
  • "The results from this phase 1 study are very encouraging in terms of potential therapeutic role of uliledlimab to treat multiple cancers, especially in patients who do not respond to PD-1/PD-L1 therapies.
  • The differentiated properties of uliledlimab may provide additional pharmacological and treatment advantages, and we look forward to advancing the development of uliledlimab both globally and in China.
  • Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment.
  • Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies.

Eledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 18, 2021
Clusters of differentiation, Medical specialties, Glycoproteins, Branches of biology, CD154, Immunology, CD40, XC2, Immunoglobulin G, Antibody, Immune system

The company\xe2\x80\x99s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.

Key Points: 
  • The company\xe2\x80\x99s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.
  • AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches.
  • The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation.
  • Eledon is headquartered in\xc2\xa0Irvine, Calif.\xc2\xa0For more information, please visit the company\xe2\x80\x99s website at www.eledon.com .\nFollow\xc2\xa0Eledon Pharmaceuticals\xc2\xa0on social media: @Eledon_Pharma and LinkedIn.\n'

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

Retrieved on: 
Tuesday, May 18, 2021
Clusters of differentiation, CD47, Cancer research, Oncology

ALX Oncology\xe2\x80\x99s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain.

Key Points: 
  • ALX Oncology\xe2\x80\x99s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain.
  • ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
  • ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML.
  • For more information, please visit ALX Oncology\xe2\x80\x99s website at www.alxoncology.com.\n'

Tumor Necrosis Factor Receptor Superfamily Member 4 - 2021 Drugs Development Market Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021
Health, Pharmaceutical, Clusters of differentiation, OX40 ligand, Branches of biology, CD134, TNF receptor superfamily, Cell biology

b'The "Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nTumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drugs in Development, 2021 provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points: 
  • b'The "Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nTumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drugs in Development, 2021 provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development and features dormant and discontinued projects.\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics.\n'

CD40 Ligand Drugs Development Market Report 2021: T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021
Health, Pharmaceutical, Clusters of differentiation, Branches of biology, Immune system, Medical specialties, Cytokines, Protein superfamilies, Single-pass transmembrane proteins, CD40, Tumor necrosis factor superfamily, CD154, Cell biology, Trail

b'The "CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nCD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021 provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points: 
  • b'The "CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nCD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021 provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development and features dormant and discontinued projects.\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics.\n'

Transcenta Announces Updated Clinical Data from Phase I Study of pH-Dependent PD-L1 Antibody MSB2311 to Be Presented at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, May 14, 2021
Clusters of differentiation, Branches of biology, Immunology, Medical specialties, Programmed cell death protein 1, PD-L1, Tumor microenvironment, L1, E-selectin, Cancer immunotherapy, PDCD1LG2

MSB2311 blocks the interaction between PD-L1 and PD-1, which reactivates the suppressed or exhausted anti-tumor effector T cell function in the tumor microenvironment.

Key Points: 
  • MSB2311 blocks the interaction between PD-L1 and PD-1, which reactivates the suppressed or exhausted anti-tumor effector T cell function in the tumor microenvironment.
  • In addition, the binding of MSB2311 to PD-L1 results in internalization of MSB2311 and MSB2311 can dissociate from bound PD-L1 in endosome with pH level lower than 5.5.
  • Results from preclinical studies demonstrate that MSB2311 can inhibit tumor growth of PD-L1 expressing tumor cells in syngeneic mouse-model.
  • Transcenta is developing a panel of nine antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

Japan's Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application

Retrieved on: 
Friday, May 14, 2021
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Antibody-drug conjugates, Monoclonal antibodies, Breakthrough therapy, Clusters of differentiation, Enfortumab vedotin, SeaGen, Antibody-drug conjugate, Monomethyl auristatin E

In the United States, Astellas and Seagen co-promote enfortumab vedotin under the brand name PADCEV (enfortumab vedotin-ejfv).

Key Points: 
  • In the United States, Astellas and Seagen co-promote enfortumab vedotin under the brand name PADCEV (enfortumab vedotin-ejfv).
  • Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.
  • EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors [abstract].
  • Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.

Global Anti-Cd38 Antibody Pipeline Insight Report 2021 Featuring Emerging Drugs Such as Felzartamab (MOR202): MorphoSys & STI-6129: Sorrento Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Health, Pharmaceutical, Medical specialties, Clusters of differentiation, CD38, Immunology, Health care, Clinical medicine, Drug pipeline, Antibody, Orphan drugs, Isatuximab, Daratumumab

b'The "Anti-Cd38 Antibody - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Anti-CD38 antibody - Pipeline Insight, 2021 report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Anti-CD38 antibody pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.

Key Points: 
  • b'The "Anti-Cd38 Antibody - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Anti-CD38 antibody - Pipeline Insight, 2021 report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Anti-CD38 antibody pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • It further highlights the inactive pipeline products in this space.\nThis segment of the Anti-CD38 antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • The companies which have their Anti-CD38 antibody drug candidates in the most advanced stage, i.e.